204 results on '"Krenciute, Giedre"'
Search Results
2. Synapse-tuned CARs enhance immune cell anti-tumor activity
3. RASA2 ablation in T cells boosts antigen sensitivity and long-term function
4. Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity
5. Therapeutic advantage of combinatorial chimeric antigen receptor T cell and chemotherapies
6. Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
7. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
8. cBAF complex components and MYC cooperate early in CD8+ T cell fate
9. Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies
10. Rapid metabolic regulation of a novel arginine methylation of KCa3.1 attenuates T cell exhaustion.
11. Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation
12. Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
13. The Mechanisms of Altered Blood–Brain Barrier Permeability in CD19 CAR T–Cell Recipients
14. CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity
15. CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity
16. GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells
17. 289 Defining the T cell functional attributes of effective CAR T cell donors
18. 250 Manipulating T cell epigenetic programs to improve persistence against group 3 pediatric medulloblastoma
19. 263 Unveiling the role of macrophages in CAR T-cell induced remodeling of the brain tumor immune microenvironment: implications for anti-glioma adoptive immunotherapy
20. Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
21. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma
22. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
23. CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity
24. Steering CAR T cell epigenetic programs by tweaking manufacturing protocol
25. IMMU-01. EVALUATING THE IMPACT OF CAR DESIGN ON THE TUMOR IMMUNE MICROENVIRONMENT AND ANTI-TUMOR RESPONSE IN SYNGENEIC GLIOMA MODELS
26. Data from Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin
27. Abstract 1778: B7-H3-CAR T-cell therapy in immune-competent osteosarcoma models: Regnase-1 KO overcomes limited CAR T-cell expansion
28. Supplementary Figures 11-18 from Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin
29. Supplemental Figures 1 - 8 from Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
30. Data from Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies
31. Supplementary Figures from Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models
32. Data from Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
33. Data from Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models
34. Figures S1-S11 from Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies
35. Supplemental Table 1 from Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
36. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma
37. cBAF complex components and MYC cooperate early in CD8+T cell fate
38. CD47 expression is critical for CAR T-cell survival in vivo
39. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
40. Structural Changes in Peptide-Scfv Bispecific Cars Impact T Cell Effector Function Against Acute Myeloid Leukemia
41. Establishing Immunocompetent Leukemia Models to Investigate the Impact of CAR T Cells on the Immune Microenvironment and Bone Marrow Niche
42. EXTH-40. DIPGS SUPPRESS THE EFFICACY OF T CELL THERAPIES THROUGH DYSFUNCTIONAL IMMUNE SYNAPSE FORMATION
43. 231 Dysfunctional immune synapses restrain anti-DIPG activity of CAR T cells
44. Augmenting CAR NK cell Anti-tumor Activity by Synapse Tuning
45. Nuclear BAG6-UBL4A-GET4 Complex Mediates DNA Damage Signaling and Cell Death
46. IMMU-01. Combining CD28 and 4-1BB costimulationin trans enhances the anti-glioma efficacy and persistence of B7-H3 CAR T cells in immune-competent brain tumor models
47. The SWI/SNF canonical BAF complex and c-Myc cooperate to promote early fate decisions in CD8+ T cells
48. Analysis of the Human Endogenous Coregulator Complexome
49. GRP78, a New CAR T Cell Target for Solid and Brain Tumors
50. T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.